Skip to main content

Versant Venture Capital VI, L.P.'s Form 4 filing

LENZ Therapeutics, Inc. (LENZ) · filed Aug 19, 2025

Accession no.
0000950170-25-110163
Filed
Aug 19, 2025, 4:51 PM ET
Trade date
Aug 15-18, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $10.3M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Versant Venture Capital VI, L.P.CIK 000168788010% Owner
Versant Venture Capital VII, L.P.CIK 000175026610% Owner
Versant Ventures VI GP-GP, LLCCIK 000177765210% Owner
Versant Ventures VI GP, L.P.CIK 000177765410% Owner
Versant Ventures VII GP, L.P.CIK 000177765510% Owner
Versant Ventures VII GP-GP, LLCCIK 000177765610% Owner
Versant Vantage II, L.P.CIK 000183223510% Owner
Versant Vantage II GP-GP, LLCCIK 000183978910% Owner
Versant Vantage II GP, L.P.CIK 000183979010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2025Common StockSSaleDisposed−145,051$39.50−$5,729,514.51,430,848Direct
Aug 15, 2025Common StockSSaleDisposed−69,949$39.50−$2,762,985.5977,963Indirect
Aug 18, 2025Common StockSSaleDisposed−30,628$38.56−$1,181,049.371,400,220Direct
Aug 18, 2025Common StockSSaleDisposed−15,085$38.56−$581,694.19962,878Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)